Keith Regnante

Biography

 Mr. Regnante joined WAVE as Chief Financial Officer in August 2016. Mr. Regnante has more than 15 years of biotechnology experience and has held a number of senior financial leadership positions over that time. Prior to his current position, Mr. Regnante was a Vice President, Finance at Shire Pharmaceuticals serving on both the Finance and R&D leadership teams. Previously, Mr. Regnante held a number of positions of increasing responsibility at Biogen including leading the Corporate Finance, R&D and Business Development finance teams. During this time, he served on teams that closed a number of high-profile deals including the merger with IDEC and the in-licensing and eventual acquisitions of two multiple sclerosis drugs, TYSABRI and TECFIDERA. Mr. Regnante was also a member of Biogen's Investor Relations function and served on the team charged with responding to a proxy challenge from a major shareholder activist. Prior to Biogen, Mr. Regnante was a Consultant at The Boston Consulting Group. Mr. Regnante received his MBA from the Sloan School of Management at MIT and is a Phi Beta Kappa graduate of Tufts University where he earned his BA in Economics.

Research Interest

 Pharma